Structural Genomics Consortium (SGC)
@thesgconline
Followers
3K
Following
1K
Media
364
Statuses
4K
A public-private partnership supporting the discovery of medicines through open science. Sharing our news, science and reagents!
Canada USA Germany Sweden UK
Joined April 2010
RT @rsc_medchem: Also in this month's issue is an update on Target 2035 from @CherylArrowsmi1, Stefan Knapp and colleagues covering the eff….
pubs.rsc.org
Target 2035 is a global initiative that seeks to identify a pharmacological modulator of most human proteins by the year 2035. As part of an ongoing series of annual updates of this initiative, we...
0
4
0
The AIRCHECK Workshop isn't just another conference! It is an exclusive opportunity to learn, experiment, and get ahead of the curve in ML/AI-driven hit discovery. Register now:
event.fourwaves.com
We are uniting experts in ML, computational chemistry, and drug discovery to get hands-on experience with AIRCHECK. Co-developed by SGC and @UHN, AIRCHECK is an open data platform designed to enhance predictive models in drug discovery. Register here:
0
1
2
We are uniting experts in ML, computational chemistry, and drug discovery to get hands-on experience with AIRCHECK. Co-developed by SGC and @UHN, AIRCHECK is an open data platform designed to enhance predictive models in drug discovery. Register here:
0
3
5
RT @geordifrere: A rigorous study of UPS tool compounds for #degrader evaluation is published by Stefan Knapp @thesgconline in ACS Chemical….
0
6
0
RT @TheNeuro_MNI: Researchers at @thesgconline and The Neuro, along with scientists from 11 major antibody manufacturers, have developed an….
0
1
0
We co-hosted " @target2035 – A Public-Private Partnership to Accelerate Hit-Finding" along with @ucl and @pfizer. 50 leaders from the pharmaceutical industry, academia, and funding organizations discussed how AI and ML can transform drug discovery.
0
1
5
RT @antolin_aa: #MAINFRAME is launching! This international, #OpenScience Network brings #MachineLearning & #compchem scientists together t….
0
3
0
We just launched #MAINFRAME! This international, #OpenScience Network brings #MachineLearning & #compchem scientists together to create open-source algorithms & benchmarks for tackling real-world challenges in #DrugDiscovery. Join us:
0
1
7
RT @JCIM_JCTC: CACHE Challenge #1: Targeting the WDR Domain of LRRK2, A Parkinson’s Disease Associated Protein.@Che….
pubs.acs.org
The CACHE challenges are a series of prospective benchmarking exercises to evaluate progress in the field of computational hit-finding. Here we report the results of the inaugural CACHE challenge in...
0
4
0
Supported by @UofTDSI, a program led by @mattschap.will provide trainees with the skills necessary to interpret complex experimental data and drive breakthroughs in drug discovery. Registration for the first 9-week bootcamp is now open.
0
3
4
New episode for our Target 2035 Podcast Series 🎧.@MilkaKostic talks with @aledmedwards to unpack his journey from a traditional research scientist to a passionate open science advocate. Listen here:
0
2
2
A summary of the efforts of @EUbOPEN, a public-private partnership dedicated to create, distribute and annotate the largest openly available set of high-quality chemical modulators for human proteins.
pubs.rsc.org
Target 2035 is a global initiative that seeks to identify a pharmacological modulator of most human proteins by the year 2035. As part of an ongoing series of annual updates of this initiative, we...
0
2
3
We have joined the Bluesky community! Follow us to stay updated on our latest research, collaborations, and efforts to shape the future of drug discovery.
0
0
1
How does EZH2 inhibition make atypical teratoid rhabdoid tumor cells vulnerable to therapy?.A collaborative study using UNC1999, a high-quality chemical probe developed through a collaboration between the SGC @UNCPharmacy.
www.nature.com
Nature Communications - Here the authors suggest that in Atypical Teratoid Rhabdoid Tumors, EZH2 inhibition triggers a viral mimicry response via the activation of genes with intronic IR-Alu...
0
0
0
We report four DCAF1-based PROTACs with endogenous and exogenous WDR5 degradation effects and high-resolution crystal structures of the ternary complexes of DCAF1-PROTAC-WDR5. #PROTACs #DCAF1 #WDR #DrugDiscovery #OpenScience.
www.nature.com
Nature Communications - The authors show that DCAF1, a substrate receptor of CUL4 and EDVP E3 ligases, can be recruited by PROTACs to degrade the cancer drug target, WDR5. They also report the...
0
0
2
A comprehensive study that offers validated ligands for future autophagosome tethering compound (ATTEC) development and advances targeted protein degradation strategies.
www.nature.com
Nature Communications - Autophagosome tethering compounds (ATTECs) are small molecule degraders hijacking the autophagy system. Here, the authors show that current ATTEC ligands did not bind to...
0
0
4
A 2024 update on @Chemical_probes highlights a significant expansion in the number of chemical probes and human protein targets, along with major improvements in expert review processes and user engagement.
academic.oup.com
Abstract. The Chemical Probes Portal (www.chemicalprobes.org) is a free, public resource, based on expert-reviews, that supports the assessment, selection
0
3
7
A fully open framework for DEL-ML hit discovery. We replace explicit DEL compound structures with ML-ready chemical fingerprints, enabling the broad scientific community to advance DEL-ML models and refine discovery methods. All data available on AIRCHECK.
0
2
3
A well anticipated overview highlighting the first CACHE challenge, which brought together 23 research teams from 10 countries to collectively predict 1,955 compounds targeting LRRK2-a protein linked to #ParkinsonsDisease.
pubs.acs.org
The CACHE challenges are a series of prospective benchmarking exercises to evaluate progress in the field of computational hit-finding. Here we report the results of the inaugural CACHE challenge in...
0
8
14
RT @Chemical_probes: 🚨 New publication alert! 🚨.Our latest update on the Chemical Probes Portal is live! 🎉. 📜 Read the paper: https://t.co/….
0
4
0